ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Protective effect of dapagliflozin against phenytoin-induced cerebellar dysfunction and histological alterations in rats: the role of SIRT1/Nrf2/HO-1 pathway.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebellar dysfunction is a common issue emerges with long-term phenytoin use. This investigation was designed to test the protective role of sodium-glucose transporter 2 inhibitor (SGLT2I), dapagliflozin (DAPA) against cerebellar disorder accompanying phenytoin therapy in rats. Twenty-four adult male Wister rats were randomized into the control, phenytoin, and phenytoin + DAPA groups. Cerebellar functions were evaluated for all rats; then, cerebellar malondialdehyde (MDA), total antioxidant capacity (TAC), tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and heme oxygenase-1 (HO-1) were determined. Histopathological examination of rats' cerebelli and immunohistochemical analysis of cerebellar nuclear factor erythroid 2-related factor-2 (Nrf2) and silent information-regulated transcription factor 1 (SIRT1) were also conducted. Phenytoin-treated rats presented a marked cerebellar dysfunction in the form of increased ataxia score and disturbed footprints in relation to control rats. Besides, cerebellar MDA, TNF-α, and IL-6 were highly elevated, while cerebellar TAC and HO-1 were apparently reduced in phenytoin-treated rats. Histological features of cerebellar degeneration and atrophy were obviously detected as well as attenuated cerebellar expression of Nrf2 and SIRT1. Concomitant DAPA and phenytoin administration resulted in a clear amelioration in cerebellar functions and morphology with better redox and inflammatory conditions than phenytoin rats. It also enhanced the cerebellar expression of HO-1, Nrf2, and SIRT1. Eventually, inhibition of SGLT2 via DAPA could protect from the cerebellar damaging effect of phenytoin in rats. Such protective impression could be a result of combating cerebellar oxidative stress and inflammation and upregulation of cerebellar SIRT1/Nrf2/HO-1 axis pathway.
Indexed as
Identifiers
42803965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.